First real-world study suggests when people with COVID-19 are most infectious
A new NIHR funded study of 57 people with mild COVID-19 estimates how long people are infectious for and when they can safely leave isolation.
- Published: 19 August 2022
News
Latest news
Filter results
Latest news
NIHR welcomes MHRA approval of Moderna Omicron COVID-19 booster
NIHR-supported Moderna Omicron bivalent COVID-19 vaccine booster receives UK approval from MHRA
- Published: 15 August 2022
COVID-19 restrictions not directly linked to distress in England
People in England continued to feel distressed even after all legal COVID-19 restrictions ended in February 2022, suggests new research funded by the NIHR.
- Published: 05 August 2022
Hair and libido loss join fatigue and brain fog among list of long COVID symptoms
A study funded by NIHR and UK Research and Innovation has found that people with long COVID experience a wider set of symptoms than previously thought, including hair loss and sexual dysfunction.
- Published: 25 July 2022
COVID-19 vaccine study calls on pregnant women to help build upon booster dose guidance
Preg-CoV, a COVID-19 vaccine study, is calling on pregnant women to join hundreds of volunteers and help researchers find the most effective use of boosters.
- Published: 19 July 2022
Sex, age and existing health problems increase risk of long COVID
Women, people aged 50-60, and people with poor pre-pandemic mental or physical health are more at risk of long COVID, according to research funded by the NIHR and UK Research and Innovation.
- Published: 29 June 2022
Interrupting treatment of vulnerable people on immune-suppressing medicines doubles their antibody response to COVID-19 booster vaccination
Interrupting the treatment of vulnerable people on long-term immune supressing medicines for two weeks after a COVID-19 booster vaccination can double their antibody response to the jab, new research finds.
- Published: 28 June 2022
COVID-19 vaccine study supports flexible intervals in mixed Pfizer and Oxford/AstraZeneca schedules
A standard two-dose Pfizer-BioNTech or Oxford-AstraZeneca vaccine schedule showed a greater antibody increase when given at a 12-week interval, compared to a four-week interval.
- Published: 09 June 2022
COVID-19 vaccination associated with reduced risk of long COVID
An NIHR-supported study of more than 28,000 people has shown that vaccination against COVID-19 is associated with a moderate reduction in the risk of experiencing long COVID.
- Published: 30 May 2022
Com-COV vaccine study to analyse 3rd dose booster options for 12 to 15 year-olds
Com-COV 3 to test multiple options for third booster dose COVID-19 vaccines for young people aged 12 to 15 years old
- Published: 26 May 2022
Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study
COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from the NIHR-supported COV-BOOST study.
- Published: 10 May 2022
Researchers create new tool to assess symptoms of long COVID
Researchers have worked with patients to develop a comprehensive tool to assess the symptoms of long COVID and their impact on everyday life.
- Published: 27 April 2022
COVID-19 vaccine boosters give well-maintained immunity three months on, finds NIHR-supported COV-BOOST trial
The latest results from the UK’s COV-BOOST study, led by University Hospital Southampton, have shown prolonged immune responses following third doses of several COVID-19 vaccines.
- Published: 21 April 2022
NIHR welcomes UK approval of Valneva COVID-19 vaccine
Following rigorous clinical trials supported by the NIHR and thorough data analysis, the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the Valneva COVID-19 vaccine for UK use.
- Published: 14 April 2022
Antiviral treatment Paxlovid investigated through PANORAMIC study
The NIHR-supported PANORAMIC trial is investigating a new COVID-19 antiviral treatment, Paxlovid, among vulnerable groups in the community.
- Published: 12 April 2022
Genetic study gives further details into severe COVID-19
The world’s largest study of the genetics of critical COVID-19, has revealed details about some of the biological mechanisms behind the severe form of the disease
- Published: 07 March 2022
RECOVERY Trial shows baricitinib reduces deaths in COVID-19 hospitalised patients
The NIHR-supported RECOVERY trial has found that baricitinib, an anti-inflammatory rheumatoid arthritis drug, reduces deaths in patients hospitalised for COVID-19 by around one-fifth.
- Published: 03 March 2022
UK volunteers to receive Moderna Omicron COVID-19 booster vaccine in clinical study
One of the world’s first Omicron-specific COVID-19 variant vaccines is to be trialled at multiple sites across the UK, as the biotechnology company Moderna, Inc works alongside the NIHR.
- Published: 16 February 2022
New definitions for long COVID developed with patients and carers
Researchers have developed new definitions for what long COVID is and the key effects in children and adults, which will help harmonise research and improve understanding of the condition.
- Published: 08 February 2022
NIHR welcomes UK approval of the Novavax COVID-19 vaccine
The Medicines and Healthcare products Regulatory Agency (MHRA) has today authorised Novavax’s COVID-19 vaccine for use in the UK. This follows rigorous clinical trials supported by NIHR and a thorough analysis of the data by experts at the MHRA
- Published: 03 February 2022
Lung abnormalities found in long COVID patients with breathlessness
Researchers have identified abnormalities in the lungs of long COVID patients with breathlessness but whose other tests are normal.
- Published: 29 January 2022
COVID-19 antivirals study UK’s fastest ever recruiting trial of its kind
An NIHR-funded clinical trial investigating new antiviral treatments for COVID-19 has become the UK’s fastest ever recruiting interventional study delivered through primary care.
- Published: 25 January 2022
COVID-19 vaccine lower booster dose study launches across UK
Young adults have a stronger immune response to vaccines than older adults, and results from COVID-19 vaccine studies have suggested lower doses of the Pfizer or Moderna COVID-19 vaccines may give as good an immune response in young adults as higher doses.
- Published: 18 January 2022
Early data for multivariant COVID-19 vaccine booster shows promise
The first results of an early trial of a multivariant COVID-19 vaccine booster, launched in September 2021 and supported by the NIHR, has released positive data.
- Published: 04 January 2022
Demographic and household factors drive difference in COVID-19 infection risk for healthcare workers from ethnic minority groups
The differences in COVID-19 infection risk between ethnic minority healthcare workers and their white colleagues is likely due to home and work factors rather than biology, according to the largest and most detailed study on the subject.
- Published: 22 December 2021